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“From the very commencement the student should set out to
witness the progress and eﬀects of sickness and ought to perse-
vere in the daily observation of disease during the whole period
of his studies.”
It was Dr. Robert J. Graves who used to pronounce this
statement at the inauguration of his yearly university lectures
in Dublin. This was in the nineteen century and he had
onlyjustdescribed Graves’disease,themost commonhyper-
thyroid condition that is so widely recognized today. There
could be at least two complementary ways of interpreting
Dr. Graves’ perennial advice. The ﬁrst way is from a practical
viewpoint. It emphasizes the importance of observation and
monitoring clinical evolution. This is an important good-
practice guide for doctors (and students) that are at a
patient’s bedside. This practical approach promotes a deep
scrutiny of the disease, taking into consideration that it is
not an abstract concept, but an ailment embodied in a given
patient.ThesecondinterpretationofGraves’statementcould
be more theoretical. Thus the signiﬁcance of the statement
supports the concept of clinical and laboratory research.
Physicians must participate in research at all levels: basic,
translational, and clinical. Dr. Graves’ counsel encourages
efforts to achieve a deep knowledge of disease as individual
entities. Therefore, both objectives, practical and theoretical,
are closely entwined—laboratory advances connected to
the bedside—what we now call translational medicine.
Unfortunately, this link is often weak.
Since 1835, when Graves described his disease, dramatic
progress has been made in our knowledge of the illness. Dur-
ing these nearly two centuries, we have come to understand a
variety of molecular, genetic, and autoimmune mechanisms
that give rise to and maintain the disease. However, it is also
true that despite recent advances, the clinical management
of Graves’ disease has changed very little over the last
few decades. Nevertheless, thanks to a group of outstand-
ing physician-investigators able to integrate the laboratory
with the bedside, we sense that exciting changes in the
management of Graves’ disease are at hand. Currently,
for instance, there are several molecular target therapies
under development that will signiﬁcantly alter the clinical
management of the disease within the next few years. This
special issue is intended to highlight some of the most recent
breakthroughs in this area. The issue includes a complete
overview: from basic reviews to clinical papers through
translational studies.
T. F. Davies et al. summarizes the new genetic insights
into autoimmune thyroid diseases (AITDs), a complex topic
that is actively being investigated. At present, more than
twenty genes have been associated with AITD that can
be categorized into two groups: immune regulatory genes
(which are common to other autoimmune diseases) and
thyroid-speciﬁc genes. Despite the described gene-AITD
association, the individual gene contribution to AITD devel-
opment is complex. Furthermore, no single polymorphism
seems to contribute substantially to the development of
the autoimmune reaction in thyroid diseases. The emerging
evidence indicates that some environmental and/or epige-
netic modiﬁcations over a predisposing genetic background
couldchangeindividualgeneexpression,whichsubsequently
elicits AITD manifestation. Although new genetic ﬁndings
have emphasized the identiﬁcation of the environmental
components that interact with host genetic factors in other2 Journal of Thyroid Research
autoimmune diseases, this approach has been elusive so far
for AITD. Unfortunately for the clinician, the genetic proﬁl-
ing of AITD patients is unlikely to be productive in the near
future,withthecorrespondinglimitationinthedevelopment
of new strategies in prevention and predictive treatment.
The role of microchimerism in Graves’ disease is the sub-
ject of J. C. Galofr´ e’s review article. In this paper the author
updates and reviews the main evidence that suggests a close
relationship linking fetal microchimerism and the devel-
opment of AITD. Certainly, the presence of intrathyroidal
fetal cells within the maternal thyroid is an attractive can-
didate mechanism for the modulation of Graves’ disease in
pregnancy and the postpartum period. At present, however,
microchimerism responsibility in the generation of AITD
remains a hypothesis.
In their review articles, M. ˇ Zarkovi´ c and L. H. Duntas
address an important and emerging matter: the role of
oxidative stress on the pathogenesis of Graves’ disease and
its speciﬁc treatment, respectively. M. ˇ Zarkovi´ c describes
how oxidative stress is indeed an environmental factor
that induces and maintains the development of Graves’
ophthalmopathy. Subsequently L. H. Duntas reviews the
emerging role of selenium in the treatment of Graves’
disease and ophthalmopathy. Both contributors tackle the
question of the inﬂammatory process in AITD. The imbal-
ance of the antioxidant-oxidant mechanism is described
in detail. The authors illustrate how there is an increased
production of radical oxygen species and cytokines, which
sustain the autoimmune process and perpetuate the dis-
ease. It is stressed that selenium, a potent antioxi-
dant, has been recently applied in patients with mild
Graves’ ophthalmopathy, slowing the progression of dis-
ease, decreasing the clinical activity score, and appreciably
improving the quality of life. Questions remain open to fur-
ther research such as whether enforced selenium nutritional
supplementation has the same results on Graves’ disease and
whether prolonging selenium administration may have an
impact on the prevention of disease.
S. El-Kaissi and J. R. Wall contribute with an original
researcharticle.Theauthorsstudythedeterminantsofextra-
ocular muscle volume (assessed by MRI) in 39 patients with
Graves’ disease. The study shows that patients with recently
diagnosed Graves’ disease and extraocular muscle volume
enlargement have higher serum TSH and more severe
hyperthyroidism at baseline than patients without extraoc-
ular muscle enlargement, with no diﬀerence in anti-TSH-R
antibody positivity when comparing both groups.
C. Kamath et al. summarize the role of thyrotrophin re-
ceptor antibody (TR-Ab) assays in Graves’ disease. TR-Ab
assays commonly used and widely available to clinicians,
measure thyroid-binding inhibiting immunoglobulins (TBII
or receptor assays), and do not diﬀerentiate between stimu-
lating(TRS-Ab),neutral,andblockingantibodies(TRB-Ab).
This limitation can induce confusion in managing Graves’
disease patients although the patient may be the best bio-
assay. The current 2nd-3rd generation receptor assays are
highly sensitive and speciﬁc when used to diﬀerentiate be-
tween the functional types of TR-Ab. The authors also
encourage measuring TR-Ab in pregnant women under
appropriate circumstances. Unfortunately, current data are
not conclusive about its use in predicting the outcome of
Graves’ disease after antithyroid drug therapy, as there is
a signiﬁcant variability in assay methodology, population
characteristics (e.g., their iodine intake), and study design in
published data.
An example of the inherent diﬃculties in interpretation
of positive TR-Ab signiﬁcance, as postulated in the C.
Kamath et al. review article, is illustrated by N. Takasu
and M. Matsushita original research article. The authors
study the changes in serum TRB-Ab and TRS-Ab levels in
34 TRB-Ab-positive patients with hypothyroidism and in
98 TRS-Ab-positive Graves’ patients with hyperthyroidism.
The study covers a ten-year period. Serum TRB-Ab levels
remained elevated during the entire study period in half
of the patients with initial hypothyroidism. Interestingly,
hypothyroid patients were divided according to the presence
of atrophic or goitrous autoimmune thyroiditis. Despite
the presence of positive TRB-Ab, all the patients with
the goitrous form recovered from hypothyroidism whereas
only 21% of the atrophic patients evolved to euthyroidism.
Around 10% of the positive TRS-Ab patients remained with
elevated circulating TRS-Ab levels at the end of the follow-
up and these patients continued to have hyperthyroidism
due to Graves’ disease. On the other hand, remission of
Graves’ disease occurs in 82% of patients in whom TRS-
Ab disappeared from the serum. The switch from TRB-
Ab to TRS-Ab or vice versa took place in 5.8% and 2.0%,
respectively, always inducing a change in the gland function.
The authors’ main conclusion is that positive TR-Ab may
be associated with two manifestations: hyperthyroidism and
hypothyroidism.
M. O. Hegazi and S. Ahmed review article focuses on
atypical clinical manifestations of Graves’ disease. Some of
the atypical features are speciﬁcally related to Graves’ disease
(including anemia, vomiting, jaundice, and right heart
failure), while others are also similarly found in patients with
other forms of hyperthyroidism. Pulmonary hypertension is
reported to be associated with Graves’ disease and reportedly
responds to its treatment. Such atypical signs and symptoms
should be considered suspect and should not be allowed to
delay diagnosis or unnecessary investigation.
We sincerely hope that the present volume will help
clinicians who work in the stimulating ﬁeld of thyroidology
t op e r sev e r ei nt h ed a i l yo b se rv a ti o no fd i se a sed u ri n gt h ewh o l e
period of their studies for the beneﬁt of their patients.
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